Author: Sabina Paglialunga

  • Prediabetes, the New Normal in Early Clinical Research

    Prediabetes, the New Normal in Early Clinical Research

    Prediabetes, the New Normal in Early Clinical Research

    There is a growing shift in inclusion criteria from healthy normal subjects to patient groups in early drug development. For programs with a chronic metabolic disease investigational product, prediabetes subject enrollment in early phase studies can facilitate the detection of efficacy signals and proof-of-concept [1].

    Prediabetes describes a state of glucose impairment which holds a significant risk of developing type 2 diabetes. According to the CDC, 1 in 3 Americans have prediabetes, yet only 1 out of 10 individuals are aware of their condition [2]. Risk factors for prediabetes include being overweight or obese, an estimated 80% of subjects with glucose impairment are overweight or obese [3].  Additional risk factors include 45 years of age or older, a family history of type 2 diabetes, a sedentary lifestyle, and previously having gestational diabetes [2]. Clinical research organizations can provide a helping hand in managing the disease by being committed to raising prediabetes awareness through free A1c screening during community outreach events [4] and offering resources on diabetes prevention.

    Type 2 diabetes patients can be vulnerable to hyperglycemic and hypoglycemic events during early phase placebo-controlled studies, monotherapy studies or during washout periods. Since prediabetes subjects maintain a degree of glucose control, they are less likely to experience severe glucose excursions. Therefore, a risk mitigation strategy to minimize serious glycemic changes in early dose escalation studies could include the enrollment of prediabetes subjects. In addition, to better understand a drug’s effect on glycemic parameters, intensive daily glucose tracking through continuous glucose monitoring (CGM) can provide blood glucose readings every 5-15 minutes for up to 2 weeks. To this end, CGM is recognized as the “ECG Holter-monitor for glycemia” [5].

    Nonalcoholic fatty liver disease (NAFLD) is the next major health epidemic and prediabetes is strongly associated with hepatic inflammation and fibrosis in NAFLD subjects [6]. Nonalcoholic steatohepatitis (NASH), a deleterious form of the disease can lead to liver cirrhosis, end-stage liver failure and even hepatocellular carcinoma. Using non-invasive techniques to assess steatosis, inflammation and oxidative stress, and fibrosis can expedite clinical research. These pharmacodynamic imaging and soluble biomarker analyses are essential early signals of drug efficacy to enable faster go/no-go decisions.

    Prediabetes subject enrollment in early clinical studies for weight management, Type 2 Diabetes or NASH indications offers an opportunity to examine pharmacodynamic endpoints in a population of interest while minimizing safety concerns typically observed with patient studies.

    References

    1. Paglialunga, S. The Impact of Prediabetes on Early Clinical Metabolic Disease Studies: Celerion, Technical Note. 2017.

    2. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA. 2014.

    3. Tuso P. Prediabetes and lifestyle modification: time to prevent a preventable disease. Perm J. 2014;18(3):88-93.

    4. Jaycox SH, Esposito M, Paglialunga S. Effectiveness of Community-Based HbA1c Screening as a Clinical Study Recruitment Tool. American Society for Clinical Pharmacology and Therapeutics; 2017 April 17 Washington,DC.

    5. Vigersky R, Shrivastav M. Role of continuous glucose monitoring for type 2 in diabetes management and research. J Diabetes Complications. 2017;31(1):280-7.

    6. Yilmaz Y, Senates E, Yesil A, Ergelen R, Colak Y. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. J Diabetes Complications. 2014;28(3):328-31.

  • Celerion Receives a 2017 CRO Leadership Award in Multiple Categories for Clinical Research Excellence

    Celerion Receives a 2017 CRO Leadership Award in Multiple Categories for Clinical Research Excellence

    Lincoln, NE (June 20, 2017) — Celerion, a leading clinical research organization, is pleased to announce it has received a CRO Leadership Award for the fourth time by global biopharmaceutical executives in Life Science Leader’s annual CRO Leadership Awards for 2017.

    Both large and small biopharmaceutical clients acknowledged Celerion as a CRO Leader in all five categories: Capabilities, Compatibility, Expertise, Quality and Reliability.

    Celerion was distinguished amongst 72 of their peers in the annual Contract Research Quality Benchmarking online survey conducted by Industry Standard Research. The survey queried the direct client experience across 27 different performance metrics spanning technical expertise to client service; results have been published in the May edition of Life Science Leader magazine.

    Additionally, Individual Attribute Awards were developed in response to the intangible capabilities that were identified as critical to successful collaborations. Celerion was also recognized for achievement in Data Quality, Innovative Solutions and Operational Excellence.

    Commenting on the news, Susan Thornton, President and CEO of Celerion said, “We would like to thank our clients for this recognition and their continued partnership with Celerion. For over 40 years Celerion has been at the forefront of early clinical research. Winning the CRO Leadership award highlights the value we consistently deliver to our clients. Our extensive experience and expertise in managing complex early phase studies in healthy volunteers and patients enables us to provide unique insights for successful clinical development programs.”

    About Celerion

    Translating science into medicine, Celerion is a premier provider of early clinical research and translational clinical pharmacology sciences from their global locations in North America, Europe and Asia.

    Celerion conducts First-in-Human, clinical Proof-of-Concept and patient dose response studies, cardiovascular safety and clinical pharmacology research supporting product labeling. With purpose-built clinic and laboratory facilities and highly automated technology, Celerion provides full study services including clinical study conduct, data management and biometrics, PK/PD analysis, bioanalytical services, medical writing, and regulatory and drug development program management. For more information please visit www.celerion.com.

    Media Contact:
    Karen Wills
    Executive Director, Global Marketing
    +1 508 808 9825
    media.inquiries@celerion.com 

  • Celerion Implements Biometric Fingerprint Technology and Marks Five-Year Anniversary with Verified Clinical Trials

    Celerion Implements Biometric Fingerprint Technology and Marks Five-Year Anniversary with Verified Clinical Trials

    Lincoln, NE; March 14, 2017 – Celerion, the premier provider of innovative early clinical research solutions, is pleased to announce that it has implemented Verified Clinical Trials (VCT) biometric fingerprint technology to prevent dual enrollment in clinical trials.

    Celerion was the first early-stage contract research organization (CRO) to partner with VCT to improve participant safety and clinical trial data. Over the last five years, Celerion performed nearly 50,000 verifications utilizing the VCT global clinical database registry to identify participants that are currently enrolled in other clinical studies.

    Most recently, Celerion implemented VCT’s biometric fingerprint technology to augment the accuracy and speed of the verifications performed at their facilities. The use of biometrics adds another layer of protection to ensure dual enrollment in clinical trials does not occur.

    “Our focus has always been to help our clients get their drugs to market and protect the safety and well-being of our participants. The VCT database registry enhances our ability to achieve both of those objectives,” said Phil Bach, Vice President, Global Clinical Research, Celerion. “Celerion and VCT share the same vision of applying scientific expertise and advanced technology to ensure the safety of our participants and maintain data integrity leading to successful clinical trial outcomes.”

    “Following Celerion’s lead, the majority of Phase I units across North America now utilize the VCT system every day to protect their clinical trials. VCT offers the most comprehensive and unique clinical research subject database registry to enhance the quality of both early and late stage studies globally. The system provides a level of safety to the clinical trial process that could not be attained without a solution like VCT,” said Mitchell Efros, MD FACS, CEO at VCT.

    “By joining forces five years ago, Celerion and VCT led the way in providing a solution that maximizes detection of attempted duplicate enrollment and protocol violations. This combined effort raised awareness and utilization across all phases of clinical research highlighting the need for a research subject database in the clinical trials industry. Working with Celerion’s team over the past five years has been a pleasure,” added Kerri Weingard, COO at VCT.

    About Celerion
    Translating science into medicine, Celerion is a premier provider of early clinical research and translational clinical pharmacology sciences from their global locations in North America, Europe and Asia.

    Celerion conducts First-in-Human, clinical Proof-of-Concept and patient dose response studies, cardiovascular safety and clinical pharmacology research supporting product labeling. With purpose-built clinic and laboratory facilities and highly automated technology, Celerion provides full study services including clinical study conduct, data management and biometrics, PK/PD analysis, bioanalytical services, medical writing, and regulatory and drug development program management. For more information please visit www.celerion.com.

    About Verified Clinical Trials
    Verified Clinical Trials is a forward-thinking company developed by experts active in the clinical research community to proactively improve research subject safety and data quality in clinical research trials.  Verified Clinical Trials defines itself as the world’s leader in the field of database registries in clinical trial research.  Verified Clinical Trials is the only clinical research database registry designed specifically to enhance the quality of both early and late phase trials and has the scalability to reach all sites nationally as well as on a global level.  Verified Clinical Trials offers numerous other value added services to the clinical research site, CRO, and Pharmaceutical Sponsor, that prove invaluable with regards to financial and legal issues and liabilities. For more information visit www.verifiedclinicaltrials.com.

    Media Contact:
    Michelle Maklas-Baker
    Manager, Global Marketing
    +1 732-306-7804
    media.inquiries@celerion.com 

  • Celerion Appoints Dr. Marc Hoffman as Chief Medical Officer

    Celerion Appoints Dr. Marc Hoffman as Chief Medical Officer

    Celerion Appoints Dr. Marc Hoffman as Chief Medical Officer

    Lincoln, NE (February 22, 2017) – Celerion, continues to grow in response to the evolving needs of early clinical research. With the increasing focus on evaluating drug effects in relevant patient populations earlier in development, Celerion is pleased to announce that Dr. Marc Hoffman has joined the company as Chief Medical Officer. Dr. Hoffman will have responsibility for leading the global medical staff and providing medical oversight and expertise to support early clinical research studies.

    Dr. Hoffman joins Celerion from Patient iP where he served as Chief Medical Officer, providing clinical leadership around Patient iP’s innovative platform, customer programs and related medical affairs activities. Prior to joining Patient iP, he held the roles of Chief Medical Officer and Senior Vice President and General Manager over the Biopharmaceutical Business at Theorem Clinical Research, leading the development of drugs and biologics. Previously in his career, Dr. Hoffman held positions of increasing responsibility in Medical and Scientific Affairs at Baxter, Hospira and Covance, providing senior-level strategic direction for Phase II-IV programs.

    Dr. Hoffman brings over 28 years of knowledge and experience as a physician in the pharmaceutical, device, and CRO industries to this role. He is experienced in global drug development, medical affairs, pharmacovigilance and regulatory affairs, and has a proven track record in building, managing and globalizing medical teams.

    “We are pleased to have Marc join our executive leadership team during this exciting period of growth in our company,” said Susan Thornton PhD, President and CEO. “His depth of experience in managing all aspects of global drug development in multiple therapeutic areas will not only make him a valuable asset for our organization but also for our clients.”

    About Celerion
    Translating science into medicine, Celerion is a premier provider of early clinical research and translational clinical pharmacology sciences from their global locations in North America, Europe and Asia.

    Celerion conducts First-in-Human, clinical Proof-of-Concept and patient dose response studies, cardiovascular safety and clinical pharmacology research supporting product labeling. With purpose-built clinic and laboratory facilities and highly automated technology, Celerion provides full study services including clinical study conduct, data management and biometrics, PK/PD analysis, bioanalytical services, medical writing, and regulatory and drug development program management. For more information please visit www.celerion.com.

    Media Contact:
    Michelle Maklas-Baker
    Manager, Global Marketing
    +1 732-306-7804
    media.inquiries@celerion.com

  • Celerion Announces Celexus as a Premier Safety Reporting Tool for Phase I Clinical Trials

    Celerion Announces Celexus as a Premier Safety Reporting Tool for Phase I Clinical Trials

    Celerion Announces Celexus as a Premier Safety Reporting Tool for Phase I Clinical Trials

    Lincoln, NE (November 17, 2016) – Celerion is pleased to announce a key technology addition to its early clinical development capabilities, Celexus®.

    Celexus® offers clients a first look at their early clinical research data in real-time, as it is collected in the clinics and laboratories, from a first in class web-based portal. Celexus® is a sophisticated approach to viewing, analyzing and trending clinical data during acquisition. The viewable data includes screening, recruiting, adverse events, clinical laboratory, pharmacodynamics, pharmacokinetic and bioanalytical data.

    Celexus is directly populated with data from Clinquick®, Celerion’s proprietary electronic data acqui­sition platform that captures source data directly from the clinic, eliminating the need for manual recording and transcription into a secondary electronic capture system.  Designed specifically for clients’ evolving needs, Celexus provides visual displays and the ability to define parameters to enable faster assessment of trends and identification of potential safety signals.

    Safety data visualizations include, among many others, vital signs, dosing, adverse events, ECGs and inclusion/exclusion criteria. These visualizations and source data are easily exported into multiple formats for analysis and creation of ad hoc reports.  Another highlight of Celexus is the Key Performance Indicator Dashboard which displays the progression of the study with information such as recruitment, deviations, study milestones/timelines, dosing and retention.

    “Technology is a key differentiator in the rapid transfer of information when translating science to medicine. Celerion is at the forefront of providers in the early clinical research space with respect to investing in the development of new technologies which provide speed and ease of data analysis to our pharma and biotech clients,” said Charles Rapier, Executive Director, Technical Business Solutions. “Celexus brings together key data from disparate systems into one single platform, providing real-time actionable insights to help our clients manage their drug development program.”

    “Our clients require visibility and transparency to effectively run their clinical study,” said Susan Thornton, President and CEO. “Real-time access to data has many empirical benefits such as reduced timelines, improved data quality and lower study costs.  It also provides a window into the clinical and operational data of ongoing studies which enables clients to make informed decisions and ultimately helps get their products to the market faster.”

    About Celerion 

    Translating science into medicine, Celerion is a premier provider of translational clinical pharmacology sciences from their global locations including North America, Europe and Asia.

    Celerion conducts first-in-human, clinical proof of concept and patient dose response studies, cardiovascular safety and NDA-enabling clinical pharmacology research. Celerion provides full study services including statistics, data management and biostatistics (including PK/PD analysis), and bioanalytical services. For more information please visit www.celerion.com.

    Media Contact:

    Michelle Maklas-Baker
    Marketing Manager
    +1 732 306 7804
    media.inquiries@celerion.com

     

     

  • Celerion Named Best Translational Clinical Pharmacology Company 2016

    Celerion Named Best Translational Clinical Pharmacology Company 2016

    Celerion Named Best Translational Clinical Pharmacology Company 2016

    Lincoln, NE (October 5, 2016) — Celerion is pleased to announce that it is the recipient of the 2016 International Life Sciences Award in the Best Translational Clinical Pharmacology Company category. The awards panels evaluated global nominees over a wide range of parameters including leadership in innovation, excellence in products and services, success stories and client testimonials. The results have been published in GHP’s 2016 International Life Science Awards Winners’ Supplement.

    Celerion Translates Science into Medicine, using state of the art technologies and new, innovative approaches in early clinical research. Serving clients of all sizes in the pharmaceutical and biotechnology industries, Celerion focuses on clinical pharmacology Phase I and IIa trials.

    Translational medicine, where evaluation of drug safety, tolerability and efficacy is assessed for the first time in humans, represents the cutting edge of pharmaceutical science. Celerion invests in and applies targeted technologies to support our clients’ need for greater clarity earlier in the drug development process.

    “This award highlights the innovation and commitment of Celerion to support clients’ evolving needs,” said Susan Thornton, President and CEO. “Our highly experienced team, consulting expertise, robust technologies and methodologies enable us to enhance efficiency, precision and reduce costs, helping clients get their products to the marker faster.”
     
    About Celerion
    Translating science into medicine, Celerion is a premier provider of translational clinical pharmacology sciences from their global locations including North America, Europe and Asia.

    Celerion conducts first-in-human, clinical proof of concept and patient dose response studies, cardiovascular safety and NDA-enabling clinical pharmacology research. Celerion provides full study services including statistics, data management and biostatistics (including PK/PD analysis), and bioanalytical services. www.celerion.com

    Media Contact:
    Lorraine M. Rusch, Ph.D
    Vice-President, Commercial Development
    Lorraine.rusch@celerion.com